Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 938

1.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.

Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P.

JAMA Cardiol. 2019 Jun 12. doi: 10.1001/jamacardio.2019.1739. [Epub ahead of print]

PMID:
31188392
2.

Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary findings for urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic heart faIlure Study (AKINESIS).

Murray PT, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müeller GA, Birkhahn R, Horiuchi Y, Clopton P, Taub P, Vilke GM, Barnett O, McDonald K, Mahon N, Nuñez J, Briguori C, Passino C, Maisel A.

J Card Fail. 2019 May 22. pii: S1071-9164(19)30071-5. doi: 10.1016/j.cardfail.2019.05.009. [Epub ahead of print]

PMID:
31128242
3.

Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.

Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA.

Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.

PMID:
31091993
4.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 May 14. doi: 10.1002/ejhf.1482. [Epub ahead of print]

PMID:
31087601
5.

GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population.

Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradović V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ; Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators.

JACC Heart Fail. 2019 Apr 29. pii: S2213-1779(19)30253-7. doi: 10.1016/j.jchf.2019.04.004. [Epub ahead of print]

PMID:
31042551
6.

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.

Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.

Eur J Heart Fail. 2019 Apr 29. doi: 10.1002/ejhf.1473. [Epub ahead of print]

PMID:
31033127
7.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Apr 24. doi: 10.1001/jamacardio.2019.1049. [Epub ahead of print]

PMID:
31017637
8.

Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction.

Hendriks T, Al Ali L, Maagdenberg CG, van Melle JP, Hummel YM, Oudkerk M, van Veldhuisen DJ, Nijveldt R, van der Horst ICC, Lipsic E, van der Harst P.

Eur J Radiol. 2019 May;114:6-13. doi: 10.1016/j.ejrad.2019.02.039. Epub 2019 Feb 28.

PMID:
31005178
9.

Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction.

Wolsk E, Kaye D, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, Kitzman DW, Lam CSP, van Veldhuisen DJ, Ponikowski P, Petrie MC, Hassager C, Møller JE, Gustafsson F.

JACC Heart Fail. 2019 Apr;7(4):321-332. doi: 10.1016/j.jchf.2019.01.006. Epub 2019 Mar 6.

PMID:
30852235
10.

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Mar 6. doi: 10.1002/ejhf.1437. [Epub ahead of print]

PMID:
30843353
11.

Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data.

Lameijer H, Burchill LJ, Baris L, Ruys TP, Roos-Hesselink JW, Mulder BJM, Silversides CK, van Veldhuisen DJ, Pieper PG.

Heart. 2019 Jun;105(11):873-880. doi: 10.1136/heartjnl-2018-314364. Epub 2019 Feb 21. Review.

PMID:
30792240
12.

The year in cardiology 2018: heart failure.

Cleland JGF, van Veldhuisen DJ, Ponikowski P.

Eur Heart J. 2019 Feb 21;40(8):651-661. doi: 10.1093/eurheartj/ehz010. No abstract available.

PMID:
30778534
13.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
14.

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M.

Eur Heart J. 2019 Apr 21;40(16):1287-1293. doi: 10.1093/eurheartj/ehz057.

15.

Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?

Rienstra M, Kotecha D, van Veldhuisen DJ.

Eur J Heart Fail. 2019 Apr;21(4):480-481. doi: 10.1002/ejhf.1425. Epub 2019 Jan 30. No abstract available.

PMID:
30698314
16.

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.

De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brügemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC.

Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.

PMID:
30629160
17.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jan 4. doi: 10.1007/s00392-018-1409-x. [Epub ahead of print]

PMID:
30610382
18.

Rapid right-sided deterioration in heart failure with preserved ejection fraction.

Gorter TM, van Veldhuisen DJ, Voors AA.

Eur Heart J. 2019 Feb 21;40(8):699-702. doi: 10.1093/eurheartj/ehy900. No abstract available.

PMID:
30608519
19.

Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.

Chin KL, Collier T, Pocock S, Pitt B, McMurray JJV, van Veldhuisen DJ, Swedberg K, Vincent J, Zannad F, Liew D.

Clin Res Cardiol. 2019 Jan 2. doi: 10.1007/s00392-018-1410-4. [Epub ahead of print]

PMID:
30604047
20.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
21.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
22.

Discussion forum response to Canepa et al.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2019 Feb 21;40(8):705-706. doi: 10.1093/eurheartj/ehy796. No abstract available.

PMID:
30500882
23.

Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.

Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA.

Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.

24.

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.

Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

25.

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, Ng LL.

Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338. [Epub ahead of print]

PMID:
30370976
26.

Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction.

Groot HE, Al Ali L, van der Horst ICC, Schurer RAJ, van der Werf HW, Lipsic E, van Veldhuisen DJ, Karper JC, van der Harst P.

Clin Res Cardiol. 2019 Jun;108(6):612-621. doi: 10.1007/s00392-018-1387-z. Epub 2018 Oct 26.

27.

Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, Anker SD, Dickstein K, Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Jan;21(1):112-120. doi: 10.1002/ejhf.1323. Epub 2018 Oct 19.

PMID:
30338883
28.

Maternal right ventricular function, uteroplacental circulation in first trimester, and pregnancy outcome in women with congenital heart disease.

Siegmund AS, Kampman MAM, Oudijk MA, Mulder BJM, Sieswerda GT, Koenen SV, Hummel YM, de Laat MWM, Sollie-Szarynska KM, Groen H, van Dijk APJ, van Veldhuisen DJ, Bilardo CM, Pieper PG.

Ultrasound Obstet Gynecol. 2018 Oct 17. doi: 10.1002/uog.20148. [Epub ahead of print]

PMID:
30334300
29.

Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.

Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F.

Clin Res Cardiol. 2019 May;108(5):477-486. doi: 10.1007/s00392-018-1378-0. Epub 2018 Sep 27.

PMID:
30264282
30.

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050.

PMID:
30165978
31.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.

N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.

32.

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N.

ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25.

33.

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA.

Eur Heart J. 2018 Nov 14;39(43):3867-3875. doi: 10.1093/eurheartj/ehy421.

34.

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

Linssen GCM, Jaarsma T, Hillege HL, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2018 Oct;26(10):486-492. doi: 10.1007/s12471-018-1145-x.

35.

Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.

van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M.

Eur J Heart Fail. 2018 Nov;20(11):1559-1566. doi: 10.1002/ejhf.1283. Epub 2018 Aug 1.

PMID:
30070041
36.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T.

Clin Res Cardiol. 2019 Feb;108(2):133-141. doi: 10.1007/s00392-018-1331-2. Epub 2018 Jul 26.

PMID:
30051179
37.

Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review.

Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG.

Thromb Res. 2018 Sep;169:123-127. doi: 10.1016/j.thromres.2018.07.022. Epub 2018 Jul 19. Review.

PMID:
30036784
38.

OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.

van der Pol A, Gil A, Tromp J, Silljé HHW, van Veldhuisen DJ, Voors AA, Hoendermis ES, Grote Beverborg N, Schouten EM, de Boer RA, Bischoff R, van der Meer P.

Cardiovasc Res. 2018 Dec 1;114(14):1871-1882. doi: 10.1093/cvr/cvy187.

PMID:
30032247
39.

Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.

Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.

Circ Heart Fail. 2018 Jul;11(7):e004926. doi: 10.1161/CIRCHEARTFAILURE.118.004926.

PMID:
29997240
40.

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.

Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

PMID:
29980595
41.

Author Correction: Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study.

Van Der Ende MY, Hendriks T, Van Veldhuisen DJ, Snieder H, Verweij N, Van Der Harst P.

Sci Rep. 2018 Jul 3;8(1):10290. doi: 10.1038/s41598-018-27848-6.

42.

Waist-to-hip ratio and mortality in heart failure.

Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC.

Eur J Heart Fail. 2018 Sep;20(9):1269-1277. doi: 10.1002/ejhf.1244. Epub 2018 Jul 2.

43.

Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions.

van der Ende MY, Said MA, van Veldhuisen DJ, Verweij N, van der Harst P.

Cardiovasc Res. 2018 Jul 15;114(9):1209-1225. doi: 10.1093/cvr/cvy083.

PMID:
29912321
44.

Heart failure with preserved ejection fraction: from mechanisms to therapies.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2018 Aug 7;39(30):2780-2792. doi: 10.1093/eurheartj/ehy301.

PMID:
29905796
45.

Atrial fibrillation is more troublesome in heart failure patients with preserved compared to those with reduced ejection fraction.

Rienstra M, van Veldhuisen DJ.

Int J Cardiol. 2018 Sep 1;266:155-156. doi: 10.1016/j.ijcard.2018.04.114. No abstract available.

PMID:
29887436
46.

Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA.

Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.

PMID:
29855124
47.

Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease.

Lameijer H, van Slooten YJ, Jongbloed MRM, Oudijk MA, Kampman MAM, van Dijk AP, Post MC, Mulder BJ, Sollie KM, van Veldhuisen DJ, Ebels T, van Melle JP, Pieper PG.

Int J Cardiol. 2018 Oct 1;268:106-112. doi: 10.1016/j.ijcard.2018.05.038. Epub 2018 May 23.

PMID:
29848449
48.

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.

Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR.

Am Heart J. 2018 May;199:51-58. doi: 10.1016/j.ahj.2017.12.001. Epub 2017 Dec 6.

PMID:
29754666
49.

Value of digoxin in patients with heart failure: new pieces to the puzzle.

van Veldhuisen DJ, Rienstra M, van der Meer P.

Eur J Heart Fail. 2018 Jul;20(7):1146-1147. doi: 10.1002/ejhf.1200. Epub 2018 Apr 20. No abstract available.

PMID:
29675974
50.

Causal Pathways from Blood Pressure to Larger Qrs Amplitudes a Mendelian Randomization Study.

Van Der Ende MY, Hendriks T, Van Veldhuisen DJ, Snieder H, Verweij N, Van Der Harst P.

Sci Rep. 2018 Apr 11;8(1):5817. doi: 10.1038/s41598-018-24002-0. Erratum in: Sci Rep. 2018 Jul 3;8(1):10290.

Supplemental Content

Loading ...
Support Center